Defining EGFR amplification status for clinical trial inclusionPim J. French, Martin J. van den Bent, Thierry Gorlia et al.|Neuro-Oncology|2019Cited by 44
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric CancerP.J. Slavish, Philip M. Potter, Liying Chi et al.|Cancer Research|2020Cited by 43
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligandYouri Hoogstrate, Pim J. French, Wies Vallentgoed et al.|Neuro-Oncology Advances|2019Cited by 17
Data from Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric CancerP.J. Slavish, Philip M. Potter, Liying Chi et al.|Unknown|2023Cited by 0
Supplementary Data from Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric CancerP.J. Slavish, Philip M. Potter, Liying Chi et al.|Unknown|2023Cited by 0